Tempest Therapeutics Q3 net loss per share narrows on lower R&D expenses

By Reuters News


Overview

  • US biotech firm posted Q3 net loss per share of $0.21, narrower than prior year

  • Company ended Q3 with $0.9 mln in cash, down from $7.7 mln at year-end 2025


Outlook

  • Company expects to present initial data from TPST-4903 Phase 1 study at upcoming conference

  • Investigator-initiated trial for TPST-4003 in myasthenia gravis or multiple sclerosis to begin Q4 2026

  • Company says existing cash expected to fund operations for less than 12 months


Result Drivers

  • R&D SPENDING SHIFT - Research and development expenses fell due to portfolio reprioritization after asset acquisition, offset by costs related to CAR-T candidates

  • HIGHER FINANCING COSTS - Financing costs rose due to commitment shares and issuance costs related to the Lincoln Park equity line of credit

  • PIPELINE ADVANCEMENT - Company cited progress in expanding its CAR-T pipeline and securing exclusive licensing agreements


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

$0.21


Reuters Recommended Reads

  • Nov 12 - Rocket Pharmaceuticals Q3 net loss narrows as R&D costs fall

  • Nov 12 - Prime Medicine Q3 loss narrows as expenses decline

  • Nov 13 - PDS Biotechnology Q3 net loss narrows on lower R&D costs


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk